{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:26:34Z","timestamp":1788179194624,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,11,27]],"date-time":"2013-11-27T00:00:00Z","timestamp":1385510400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1038\/leu.2013.361","type":"journal-article","created":{"date-parts":[[2013,11,27]],"date-time":"2013-11-27T07:34:26Z","timestamp":1385537666000},"page":"554-565","source":"Crossref","is-referenced-by-count":56,"title":["Differential expression of miR-17\u223c92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"28","author":[{"given":"M","family":"Scherr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Elder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Battmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Barzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9163-5738","authenticated-orcid":false,"given":"S","family":"Bomken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ricke-Hoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H J","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Vormoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Ottmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Pich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Hilfiker-Kleiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,27]]},"reference":[{"key":"BFleu2013361_CR1","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","volume":"109","author":"AV Moorman","year":"2007","unstructured":"Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007; 109: 3189\u20133197.","journal-title":"Blood"},{"key":"BFleu2013361_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1040-8428(00)00097-4","volume":"36","author":"D Hoelzer","year":"2000","unstructured":"Hoelzer D, Gokbuget N . Recent approaches in acute lymphoblastic leukemia in adults. Critical Rev Oncol\/Hematol 2000; 36: 49\u201358.","journal-title":"Critical Rev Oncol\/Hematol"},{"key":"BFleu2013361_CR3","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1365-2141.2011.08783.x","volume":"154","author":"S Rives","year":"2011","unstructured":"Rives S, Estella J, Gomez P, Lopez-Duarte M, de Miguel PG, Verdeguer A et al. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. BritJ Haematol 2011; 154: 600\u2013611.","journal-title":"BritJ Haematol"},{"key":"BFleu2013361_CR4","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","volume":"27","author":"KR Schultz","year":"2009","unstructured":"Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009; 27: 5175\u20135181.","journal-title":"J Clin Oncol"},{"key":"BFleu2013361_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/leu.2010.228","volume":"25","author":"S Mizuta","year":"2011","unstructured":"Mizuta S, Matsuo K, Yagasaki F, Yujiri T, Hatta Y, Kimura Y et al. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia 2011; 25: 41\u201347.","journal-title":"Leukemia"},{"key":"BFleu2013361_CR6","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/cncr.22631","volume":"109","author":"OG Ottmann","year":"2007","unstructured":"Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Duhrsen U et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 2007; 109: 2068\u20132076.","journal-title":"Cancer"},{"key":"BFleu2013361_CR7","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","volume":"113","author":"AK Fielding","year":"2009","unstructured":"Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII\/ECOG2993. Blood 2009; 113: 4489\u20134496.","journal-title":"Blood"},{"key":"BFleu2013361_CR8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1182\/blood-2004-05-1746","volume":"106","author":"B Wassmann","year":"2005","unstructured":"Wassmann B, Pfeifer H, Stadler M, Bornhauser M, Bug G, Scheuring UJ et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2005; 106: 458\u2013463.","journal-title":"Blood"},{"key":"BFleu2013361_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.2009.011221","volume":"95","author":"JM Ribera","year":"2010","unstructured":"Ribera JM, Oriol A, Gonzalez M, Vidriales B, Brunet S, Esteve J et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica 2010; 95: 87\u201395.","journal-title":"Haematologica"},{"key":"BFleu2013361_CR10","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1200\/JCO.2010.28.1287","volume":"28","author":"R Bassan","year":"2010","unstructured":"Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09\/00. J Clin Oncol 2010; 28: 3644\u20133652.","journal-title":"J Clin Oncol"},{"key":"BFleu2013361_CR11","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","volume":"116","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010; 116: 2070\u20132077.","journal-title":"Blood"},{"key":"BFleu2013361_CR12","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/leu.2012.5","volume":"26","author":"H Pfeifer","year":"2012","unstructured":"Pfeifer H, Lange T, Wystub S, Wassmann B, Maier J, Binckebanck A et al. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia 2012; 26: 1475\u20131481.","journal-title":"Leukemia"},{"key":"BFleu2013361_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jmb.2004.03.065","volume":"339","author":"A Tanzer","year":"2004","unstructured":"Tanzer A, Stadler PF . Molecular evolution of a microRNA cluster. J Mol Biol 2004; 339: 327\u2013335.","journal-title":"J Mol Biol"},{"key":"BFleu2013361_CR14","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.cell.2008.02.019","volume":"132","author":"A Ventura","year":"2008","unstructured":"Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008; 132: 875\u2013886.","journal-title":"Cell"},{"key":"BFleu2013361_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccr.2008.02.013","volume":"13","author":"F Petrocca","year":"2008","unstructured":"Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008; 13: 272\u2013286.","journal-title":"Cancer Cell"},{"key":"BFleu2013361_CR16","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1073\/pnas.0510565103","volume":"103","author":"S Volinia","year":"2006","unstructured":"Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257\u20132261.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2013361_CR17","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1158\/0008-5472.CAN-03-3773","volume":"64","author":"A Ota","year":"2004","unstructured":"Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004; 64: 3087\u20133095.","journal-title":"Cancer Res"},{"key":"BFleu2013361_CR18","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1101\/gad.1872909","volume":"23","author":"P Mu","year":"2009","unstructured":"Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P et al. Genetic dissection of the miR-17\u223c92 cluster of microRNAs in Myc-induced B-cell lymphomas. Gene Dev 2009; 23: 2806\u20132811.","journal-title":"Gene Dev"},{"key":"BFleu2013361_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/ni1575","volume":"9","author":"C Xiao","year":"2008","unstructured":"Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008; 9: 405\u2013414.","journal-title":"Nat Immunol"},{"key":"BFleu2013361_CR20","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1101\/gad.1861409","volume":"23","author":"V Olive","year":"2009","unstructured":"Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C et al. miR-19 is a key oncogenic component of mir-17-92. Gene Dev 2009; 23: 2839\u20132849.","journal-title":"Gene Dev"},{"key":"BFleu2013361_CR21","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1182\/blood-2006-09-045104","volume":"109","author":"L Venturini","year":"2007","unstructured":"Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 2007; 109: 4399\u20134405.","journal-title":"Blood"},{"key":"BFleu2013361_CR22","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1021\/pr300973q","volume":"12","author":"J Zeiser","year":"2013","unstructured":"Zeiser J, Gerhard R, Just I, Pich A . Substrate specificity of clostridial glucosylating toxins and their function on colonocytes analyzed by proteomics techniques. J Proteome Res 2013; 12: 1604\u20131618.","journal-title":"J Proteome Res"},{"key":"BFleu2013361_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/emmm.201201703","volume":"5","author":"K Rehe","year":"2013","unstructured":"Rehe K, Wilson K, Bomken S, Williamson D, Irving J, den Boer ML et al. Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Mol Med 2013; 5: 38\u201351.","journal-title":"EMBO Mol Med"},{"key":"BFleu2013361_CR24","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/leu.2012.206","volume":"27","author":"S Bomken","year":"2013","unstructured":"Bomken S, Buechler L, Rehe K, Ponthan F, Elder A, Blair H et al. Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression. Leukemia 2013; 27: 718\u2013721.","journal-title":"Leukemia"},{"key":"BFleu2013361_CR25","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1182\/blood.V91.10.3927.3927_3927_3934","volume":"91","author":"KM Klucher","year":"1998","unstructured":"Klucher KM, Lopez DV, Daley GQ . Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR\/ABL expression. Blood 1998; 91: 3927\u20133934.","journal-title":"Blood"},{"key":"BFleu2013361_CR26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nature03677","volume":"435","author":"KA O'Donnell","year":"2005","unstructured":"O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT . c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839\u2013843.","journal-title":"Nature"},{"key":"BFleu2013361_CR27","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","volume":"30","author":"AW Roberts","year":"2012","unstructured":"Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012; 30: 488\u2013496.","journal-title":"J Clin Oncol"},{"key":"BFleu2013361_CR28","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","volume":"18","author":"CM Rudin","year":"2012","unstructured":"Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 2012; 18: 3163\u20133169.","journal-title":"Clin Cancer Res"},{"key":"BFleu2013361_CR29","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.cell.2006.07.031","volume":"126","author":"KC Miranda","year":"2006","unstructured":"Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006; 126: 1203\u20131217.","journal-title":"Cell"},{"key":"BFleu2013361_CR30","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.molcel.2009.08.020","volume":"35","author":"A Lal","year":"2009","unstructured":"Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, O'Day E et al. miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to \u2018seedless\u2019 3'UTR microRNA recognition elements. Mol Cell 2009; 35: 610\u2013625.","journal-title":"Mol Cell"},{"key":"BFleu2013361_CR31","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nmeth.1247","volume":"5","author":"M Hammell","year":"2008","unstructured":"Hammell M, Long D, Zhang L, Lee A, Carmack CS, Han M et al. mirWIP: microRNA target prediction based on microRNA-containing ribonucleoprotein-enriched transcripts. Nat Methods 2008; 5: 813\u2013819.","journal-title":"Nat Methods"},{"key":"BFleu2013361_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/bioinformatics\/btp649","volume":"26","author":"W Ritchie","year":"2010","unstructured":"Ritchie W, Flamant S, Rasko JE . mimiRNA: a microRNA expression profiler and classification resource designed to identify functional correlations between microRNAs and their targets. Bioinformatics 2010; 26: 223\u2013227.","journal-title":"Bioinformatics"},{"key":"BFleu2013361_CR33","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1093\/nar\/gkm971","volume":"35","author":"M Scherr","year":"2007","unstructured":"Scherr M, Venturini L, Battmer K, Schaller-Schoenitz M, Schaefer D, Dallmann I et al. Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res 2007; 35: e149.","journal-title":"Nucleic Acids Res"},{"key":"BFleu2013361_CR34","doi-asserted-by":"publisher","first-page":"8590","DOI":"10.1038\/sj.onc.1207102","volume":"22","author":"S Cory","year":"2003","unstructured":"Cory S, Huang DC, Adams JM . The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22: 8590\u20138607.","journal-title":"Oncogene"},{"key":"BFleu2013361_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nri1568","volume":"5","author":"A Strasser","year":"2005","unstructured":"Strasser A . The role of BH3-only proteins in the immune system. Nat Rev Immunol 2005; 5: 189\u2013200.","journal-title":"Nat Rev Immunol"},{"key":"BFleu2013361_CR36","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1073\/pnas.92.12.5287","volume":"92","author":"I Sanchez-Garcia","year":"1995","unstructured":"Sanchez-Garcia I, Grutz G . Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA 1995; 92: 5287\u20135291.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2013361_CR37","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677\u2013681.","journal-title":"Nature"},{"key":"BFleu2013361_CR38","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421\u20133428.","journal-title":"Cancer Res"},{"key":"BFleu2013361_CR39","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1200\/JCO.2011.37.9339","volume":"30","author":"LD Walensky","year":"2012","unstructured":"Walensky LD . From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia. J Clin Oncol 2012; 30: 554\u2013557.","journal-title":"J Clin Oncol"},{"key":"BFleu2013361_CR40","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","volume":"29","author":"L Gandhi","year":"2011","unstructured":"Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011; 29: 909\u2013916.","journal-title":"J Clin Oncol"},{"key":"BFleu2013361_CR41","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1182\/blood-2010-11-317438","volume":"118","author":"L Bodet","year":"2011","unstructured":"Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maiga S et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood 2011; 118: 3901\u20133910.","journal-title":"Blood"},{"key":"BFleu2013361_CR42","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics and antitumour activity. The Lancet Oncol 2010; 11: 1149\u20131159.","journal-title":"The Lancet Oncol"},{"key":"BFleu2013361_CR43","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202\u2013208.","journal-title":"Nat Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2013361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2013361","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2013361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:04:26Z","timestamp":1684433066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2013361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,27]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["BFleu2013361"],"URL":"https:\/\/doi.org\/10.1038\/leu.2013.361","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,27]]}}}